SCHEMBL5032646

SCHEMBL5032646

CC(C)(CO)NS(=O)(=O)c1ccc(Cl)c(N)c1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.54
ALDH1A1 P00352 2/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
MAPT P10636 2/20 0.48
NPSR1 Q6W5P4 1/20 0.48
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
LMNA P02545 1/20 0.43
PKM P14618 1/20 0.43
TSHR P16473 2/20 0.42
THRB P10828 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
PARG Q86W56 1/20 0.41
TDP1 Q9NUW8 2/20 0.40
HSD17B2 P37059 1/20 0.40
POLB P06746 1/20 0.39
DUT P33316 1/20 0.39
RECQL P46063 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5034910 0.84 KDM4E (0.56) KDM4EALDH1A1L3MBTL1MAPTLMNA
SCHEMBL5035258 0.82 ALDH1A1 (0.51) KDM4EALDH1A1L3MBTL1LMNAPKM
SCHEMBL5035886 0.80 THRB (0.64) KDM4EALDH1A1L3MBTL1THRB
SCHEMBL30079307 0.79 TSHR (0.63) KDM4EALDH1A1L3MBTL1KMT2ATSHR
SCHEMBL5032675 0.77 ALDH1A1 (0.53) KDM4EALDH1A1L3MBTL1MAPTKMT2A
SCHEMBL1808661 0.75 VCAM1 (0.58) ALDH1A1L3MBTL1MAPTNPSR1KMT2A
SCHEMBL11430770 0.75 PKM (0.56) ALDH1A1MAPTNPSR1KMT2AMEN1
SCHEMBL11689687 0.74 VCAM1 (0.61) KDM4EALDH1A1MAPTNPSR1KMT2A
SCHEMBL10282879 0.73 ALDH1A1 (0.56) KDM4EALDH1A1L3MBTL1KMT2AMEN1
SCHEMBL4618233 0.73 LMNA (0.48) KDM4EALDH1A1L3MBTL1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1761541-B1 PYRRAZOLO-PYRIMIDINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2008-01-09 EP claimed
US-7378417-B2 Pyrazolo-pyrimidine derivatives HOFFMANN-LA ROCHE INC. (US) 2008-05-27 US disclosed
EP-1761541-B1 PYRRAZOLO-PYRIMIDINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2008-01-09 EP disclosed
EP-1761541-A1 PYRRAZOLO-PYRIMIDINE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2007-03-14 EP disclosed
WO-2005123738-A1 PYRRAZOLO-PYRIMIDINE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2005-12-29 WO disclosed
US-20050282827-A1 Pyrazolo-pyrimidine derivatives F. HOFFMANN-LA ROCHE AG (CH) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282827-A1 Pyrazolo-pyrimidine derivatives P2RX3, P2RX1, P2RX5 KDM4E 3638/4885ALDH1A1 1028/4885L3MBTL1 3462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.